复发、难治多发性骨髓瘤的新药治疗

 【摘要】　新型药物如免疫调节剂（IMiD）沙利度胺和雷利度胺及蛋白酶体抑制剂（PI）硼替佐米的应用极大地改善了复发、难治多发性骨髓瘤（MM）的临床预后。但是，也有患者对这些新型药物耐药或不能耐受。多种药物包括新一代IMiD（泊马度胺）、新一代PI（如卡非佐米、MLN9708及marizomib）、组蛋白去乙酰化酶抑制剂（如帕比司他及伏林司他）、信号转导调节剂（如哌立福新）等正在进行临床试验，它们表现出良好的抗MM活性，尤其在那些对现有新型药物耐药的患者中也有效。文章介绍现有的及处于临床研究中新型抗骨髓瘤药物在复发、难治MM患者中的应用。

Novel agents for relapsed/refractory multiple myeloma

【Abstract】　The immunomodulatory drugs (IMiD) thalidomide and lenalidomide, and the proteasome inhibitor (PI) bortezomib have dramatically improved clinical outcomes for patients with relapsed/refractory multiple myeloma(MM). But a part of patients become refractory or intolerant to these agents. Numerous agents are currently in clinical development, including new IMiD (pomalidomide), new PI (eg, carfilzomib, MLN9708, and marizomib), histone deacetylase inhibitors (eg, panobinostat and vorinostat) and signal transduction modulators (eg, perifosine), and have demonstrated promising anti-myeloma activity in patients with relapsed/refractory MM, particularly in those who are refractory to approved novel agents. This article describes antimyeloma agents currently available or in clinical development for relapsed/refractory patients.